APIDRA SOLOSTAR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for APIDRA SOLOSTAR (APIDRA SOLOSTAR).
Insulin glulisine is a recombinant human insulin analog that lowers blood glucose by binding to insulin receptors on muscle and fat cells, facilitating glucose uptake, and inhibiting hepatic glucose production.
| Metabolism | Primarily metabolized by insulin-degrading enzyme (IDE). |
| Excretion | Renal: 60-80% of dose as metabolites and parent drug; biliary/fecal: minor (20-40%) |
| Half-life | 1.0-1.5 hours (terminal elimination half-life; consistent with rapid absorption and clearance; shorter than regular human insulin) |
| Protein binding | 94% bound to albumin and other plasma proteins |
| Volume of Distribution | 0.13 L/kg (suggests limited distribution into tissues; primarily extracellular) |
| Bioavailability | Subcutaneous: approximately 100% (complete absorption from subcutaneous tissue; slight variability by injection site) |
| Onset of Action | Subcutaneous: 15-30 minutes |
| Duration of Action | Subcutaneous: 3-5 hours (dose-dependent; shorter duration with lower doses; recommended for use with longer-acting insulin) |
Subcutaneous injection, 0.2-0.4 units/kg/day divided into two or more doses; for basal-bolus therapy, total daily dose is 0.5-1.0 units/kg/day with 50-60% as prandial insulin glulisine.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 15-29 mL/min: reduce dose by 25-50%; for GFR <15 mL/min: reduce dose by 50% and monitor closely. |
| Liver impairment | For Child-Pugh Class B or C: initially reduce dose by 25-50% due to decreased gluconeogenesis. |
| Pediatric use | Children aged 6-17 years: 0.5-1.0 units/kg/day total, with 50-60% given as insulin glulisine divided into two or more injections; titrate based on glucose levels. |
| Geriatric use | Start with lower doses (e.g., 0.2-0.4 units/kg/day) and titrate slowly to avoid hypoglycemia; monitor renal function and cognitive status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for APIDRA SOLOSTAR (APIDRA SOLOSTAR).
| Breastfeeding | Insulin glulisine is a protein and likely degraded in the infant's GI tract; minimal transfer into breast milk. No M/P ratio available. Use is considered compatible with breastfeeding; monitor infant for hypoglycemia. |
| Teratogenic Risk | Insulin glulisine (APIDRA SOLOSTAR) does not cross the placenta significantly. Animal studies show no teratogenicity. In pregnant women with diabetes, poor glycemic control increases risks of congenital malformations (first trimester), macrosomia, neonatal hypoglycemia, and respiratory distress (second/third trimesters). Insulin glulisine is considered low risk when used to maintain normoglycemia. |
■ FDA Black Box Warning
Changes in insulin strength, manufacturer, type, or method of administration should be made under close medical supervision to prevent hypoglycemia.
| Common Effects | Hypoglycemia low blood glucose level Allergic reaction Injection site reactions pain swelling redness Lipodystrophy skin thickening or pits at the injection site Itching Rash Upper respiratory tract infection |
| Serious Effects |
["Hypersensitivity to insulin glulisine or any excipients","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia is the most common adverse effect. Severe hypoglycemia can cause seizures or loss of consciousness.","Changes in insulin regimen should be made cautiously and under medical supervision.","Accidental mix-ups between insulin products can occur; verify label before administration.","Hypokalemia may occur if insulin dose is too high; monitor potassium levels in patients at risk.","Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs).","Renal or hepatic impairment may require dose adjustment.","Not recommended for intravenous use."] |
Loading safety data…
| Fetal Monitoring | Monitor blood glucose and HbA1c; fetal ultrasound for anomalies; assess fetal growth (macrosomia); evaluate for preeclampsia; neonatal blood glucose monitoring after delivery. |
| Fertility Effects | No known direct effects on fertility. Uncontrolled diabetes can impair fertility; optimal glycemic control improves reproductive outcomes. |
| Food/Dietary | Absorption may be affected by high-fat or high-protein meals, potentially delaying onset; however, no specific food restrictions. Adjust dose based on pre-meal blood glucose and anticipated carbohydrate intake. Alcohol consumption may increase risk of hypoglycemia. |
| Clinical Pearls | Apidra Solostar (insulin glulisine) is a rapid-acting insulin analog with onset of action within 15 minutes, peak at 1 hour, and duration of 3-4 hours. It can be administered immediately before or within 15 minutes after starting a meal. The Solostar pen delivers doses in 1-unit increments up to 80 units. Injection sites include abdomen, thigh, or deltoid; absorption is fastest from the abdomen. Do not mix with other insulins in the same syringe. Use in insulin pumps is not recommended due to potential for precipitation. Renal or hepatic impairment may prolong duration. |
| Patient Advice | Inject Apidra within 15 minutes before or immediately after a meal. · Rotate injection sites to avoid lipodystrophy. · Do not mix with other insulins in the same syringe. · Monitor blood glucose closely and record episodes of hypoglycemia. · Keep Apidra at room temperature away from direct heat and light; do not freeze. · Do not use if solution appears cloudy or contains particles. · Dispose of used pens and needles in a sharps container. |